Hospitals
The Department of Health is responsible for the licensing and oversight of Pennsylvania’s hospitals. The department conducts the Medicare and licensure surveys, as well as complaint and incident investigations for these facilities.
For questions about how to become a licensed facility, please contact:
Division of Acute and Ambulatory Care
Room 532, Health & Welfare Building
Harrisburg, PA 17120
RA-DAAC@pa.gov
For information on how to use deemed accreditation in lieu of licensure, please complete the following form and return to the Division of Acute and Ambulatory Care.
To add new or replace old equipment or to add a new service, please complete the following form(s) and return to the Division of Acute and Ambulatory Care.
Act 43 of 2023
Background
Act 43 of 2023 requires fentanyl and xylazine testing when a urine drug screening is conducted in an emergency department within an acute care hospital for the purposes of diagnosing a patient's condition. Xylazine testing is only required if testing is available as part of the urine drug screening panel. If the urine drug screening performed under Act 43 detects fentanyl or xylazine, the de-identified results shall be reported to the Department of Health (Department). Emergency departments are expected to begin collecting data starting on May 1, 2024, with the first report due to the Department on June 1, 2024. See
54 Pa.B. 1268.
Reporting
Please submit monthly aggregate data reports to the Department using the
online form.
Informational Materials
Act 43 of 2023 requires informational materials on the dangers of human use of xylazine be provided to Commonwealth residents when fentanyl or xylazine is detected.
Frequently Asked Questions